Advertisement
"Amy and Iain bring valuable operations experience that is vital as weprepare regulatory filings in the U.S. and Europe and move forward with theanticipated commercialization of our lead product candidate, HZT-501," saidTimothy P. Walbert, president and chief executive officer. "During theirrespective careers, Amy and Iain have been instrumental in the growth ofstart-up as well as established biotech and pharmaceutical companies and theirleadership will be an important part of Horizon's future growth."
Advertisement
Ms. Grahn has more than 20 years pharmaceutical industry experiencespanning pre-clinical research to sales, with a primary focus on clinicaloperations. Ms. Grahn was most recently vice president of clinical operationsat MedGenesis Therapeutix Inc. in British Columbia, Canada where she wasresponsible for strategic planning, development and implementation of clinicaland pre-clinical development plans for therapeutic agents delivered via theMedGenesis convection-enhanced delivery (CED) platform.
During her career, Ms. Grahn has held various senior level positions atNeopharm, Inc., Takeda Pharmaceuticals North America, Inc., G.D. Searle &Company and Abbott Laboratories.
At Horizon, Ms. Grahn will lead all clinical operations activities. Ms.Grahn has a master's degree in biochemistry from Illinois Institute ofTechnology in Chicago and a bachelor's degree in chemistry and biology fromKnox College in Galesburg, Ill.
Mr. Duncan has more than 20 years executive-level management experience ininternational, general and operations management. Mr. Duncan was a co-founderof Corus Pharma, Inc., which was purchased by Gilead Sciences, Inc. and wasmost recently vice president of operations at Corus where he was integral inthe development and manufacturing of aztreonam lysinate for inhalation (AI).Additionally, he supervised the formulation and development of threeadditional drug candidates.
Prior to Corus, Mr. Duncan held positions at Pathogenesis Inc. andLyondell Chemical.
At Horizon, Mr. Duncan will lead all manufacturing, quality control andsupply chain activities. Mr. Duncan has a bachelor's degree in biology fromTrent University in Ontario, Canada.
The Company recently announced that its lead product HZT-501 met theprimary endpoints in two Phase 3 clinical studies, REDUCE-1 and REDUCE-2 (TheRegistration Endoscopic Study to Determine Ulcer Formation of HZT-501 Comparedto Ibuprofen: Efficacy and Safety Study). In REDUCE-1, 24-week treatment withHZT-501 resulted in a statistically significant reduction in gastric ulcersversus treatment with ibuprofen alone. In REDUCE-2, 24-week treatment withHZT-501 resulted in a statistically significant reduction in gastric and/orduodenal ulcers versus treatment with ibuprofen alone.
The trials were conducted via a Special Protocol Assessment (SPA) with theU.S. Food and Drug Administration (FDA) and based on the results the Companyplans to submit filings to U.S. and European regulatory authorities in 2009.
About Horizon Therapeutics
Horizon Therapeutics, Inc. is a late-stage biopharmaceutical companyfocused on the development and commercialization of therapies for thetreatment of mild-to-moderate pain and arthritis. Horizon's clinicalportfolio includes innovative combination therapies in early- and late-stagedevelopment that are designed to improve safety, efficacy and patientcompliance. For more information about the company and its products, pleasevisit http://www.horizontherapeutics.com.
SOURCE Horizon Therapeutics, Inc.
